These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 18978495

  • 1. Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials.
    Gunzler SA, Pavel M, Koudelka C, Carlson NE, Nutt JG.
    Clin Neuropharmacol; 2009; 32(2):97-102. PubMed ID: 18978495
    [Abstract] [Full Text] [Related]

  • 2. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
    Nutt JG, Carter JH, Carlson NE.
    Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
    [Abstract] [Full Text] [Related]

  • 3. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
    Pahwa R, Koller WC, Trosch RM, Sherry JH, APO303 Study Investigators.
    J Neurol Sci; 2007 Jul 15; 258(1-2):137-43. PubMed ID: 17466338
    [Abstract] [Full Text] [Related]

  • 4. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ.
    Clin Ther; 2009 Jan 15; 31(1):89-98. PubMed ID: 19243709
    [Abstract] [Full Text] [Related]

  • 5. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
    Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL, EASE-PD Adjunct Study Investigators.
    Neurology; 2007 Apr 03; 68(14):1108-15. PubMed ID: 17404192
    [Abstract] [Full Text] [Related]

  • 6. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H.
    Mov Disord; 2007 Jan 15; 22(2):179-86. PubMed ID: 17094088
    [Abstract] [Full Text] [Related]

  • 7. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
    O'Sullivan JD, Said CM, Dillon LC, Hoffman M, Hughes AJ.
    Mov Disord; 1998 Nov 15; 13(6):900-6. PubMed ID: 9827613
    [Abstract] [Full Text] [Related]

  • 8. Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study.
    Lou JS, Dimitrova DM, Park BS, Johnson SC, Eaton R, Arnold G, Nutt JG.
    Clin Neuropharmacol; 2009 Nov 15; 32(6):305-10. PubMed ID: 19620846
    [Abstract] [Full Text] [Related]

  • 9. Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.
    Lou JS, Kearns G, Benice T, Oken B, Sexton G, Nutt J.
    Mov Disord; 2003 Oct 15; 18(10):1108-14. PubMed ID: 14534913
    [Abstract] [Full Text] [Related]

  • 10. Transcranial magnetic stimulation over dorsolateral prefrontal cortex in Parkinson's disease.
    del Olmo MF, Bello O, Cudeiro J.
    Clin Neurophysiol; 2007 Jan 15; 118(1):131-9. PubMed ID: 17097342
    [Abstract] [Full Text] [Related]

  • 11. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK, Goetz CG, Leurgans S, Fan W, Nguyen T, Hsu A.
    Clin Neuropharmacol; 2009 Jan 15; 32(4):189-92. PubMed ID: 19620848
    [Abstract] [Full Text] [Related]

  • 12. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease.
    Pfeiffer RF, Gutmann L, Hull KL, Bottini PB, Sherry JH, APO302 Study Investigators.
    Parkinsonism Relat Disord; 2007 Mar 15; 13(2):93-100. PubMed ID: 17055329
    [Abstract] [Full Text] [Related]

  • 13. Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study.
    Gunzler SA, Koudelka C, Carlson NE, Pavel M, Nutt JG.
    Arch Neurol; 2008 Feb 15; 65(2):193-8. PubMed ID: 18268187
    [Abstract] [Full Text] [Related]

  • 14. Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson Disease.
    Goberman AM.
    Med Sci Monit; 2005 Mar 15; 11(3):CR109-16. PubMed ID: 15735562
    [Abstract] [Full Text] [Related]

  • 15. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A, Parkinson REGAIN Study Group.
    Mov Disord; 2006 Dec 15; 21(12):2110-5. PubMed ID: 17013922
    [Abstract] [Full Text] [Related]

  • 16. Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance.
    Scholtissen B, Verhey FR, Adam JJ, Weber W, Leentjens AF.
    Clin Neuropharmacol; 2006 Dec 15; 29(5):276-85. PubMed ID: 16960473
    [Abstract] [Full Text] [Related]

  • 17. Reaction time and movement time after embryonic cell implantation in Parkinson disease.
    Gordon PH, Yu Q, Qualls C, Winfield H, Dillon S, Greene PE, Fahn S, Breeze RE, Freed CR, Pullman SL.
    Arch Neurol; 2004 Jun 15; 61(6):858-61. PubMed ID: 15210522
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
    Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, Müller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H, German Coenzyme Q(10) Study Group.
    Arch Neurol; 2007 Jul 15; 64(7):938-44. PubMed ID: 17502459
    [Abstract] [Full Text] [Related]

  • 19. Effect of ropinirole on visuo-motor test in newly diagnosed Parkinson's disease patients.
    Badarny S, Stern A, Susel Z, Honigman S, Hocherman S.
    Acta Neurol Scand; 2006 May 15; 113(5):294-300. PubMed ID: 16629764
    [Abstract] [Full Text] [Related]

  • 20. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
    LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM, 6002-US-005 Study Group.
    Ann Neurol; 2008 Mar 15; 63(3):295-302. PubMed ID: 18306243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.